Global Tyrosine Kinase Inhibitors Market Opportunities 2024, Forecast To 2033
8 Mar, 2024
The tyrosine kinase inhibitors market has experienced strong growth, increasing from $53.72 billion in 2023 to $58.69 billion in 2024, with a CAGR of 9.3%. This growth is driven by factors such as growing understanding of cancer signaling pathways and investments in research and development. Forecasts indicate continued strong growth, with the market expected to reach $81.41 billion in 2028, boasting a CAGR of 8.5%. Key drivers include biomarker-driven therapies and drug delivery innovations. Major trends include resistance mitigation strategies and development of non-oncology applications.
Global Tyrosine Kinase Inhibitors Market Key Driver
The tyrosine kinase inhibitors market is expanding due to the increasing prevalence of cancer. Cancer remains a significant health concern globally, driving the demand for targeted therapies like tyrosine kinase inhibitors. The American Cancer Society projects a notable increase in cancer cases, emphasizing a substantial market driver for tyrosine kinase inhibitors.
Get A Free Sample Of The Global Tyrosine Kinase Inhibitors Market ReportGlobal Tyrosine Kinase Inhibitors Market Segments
The tyrosine kinase inhibitors market covered in this report is segmented –
1) Type:BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
2) Distribution Channel:Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
3) Application:Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications
By Geography: The countries covered in the tyrosine kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the tyrosine kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Tyrosine Kinase Inhibitors Industry Players
Pfizer Inc.; Johnson And Johnson Private Limited.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca Plc.; GlaxoSmithKline plc; Eli Lilly and Company; Amgen Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Eisai Co. Ltd; Incyte Corporation; Dr. Reddy's Laboratories Ltd.; Exelixis Inc.; Array BioPharma Inc.; Glenmark Pharmaceuticals Ltd; Blueprint Medicines Corporation; Loxo Oncology Inc.; Rigel Pharmaceuticals Inc.; Deciphera Pharmaceuticals LLC; Epizyme Inc.; Turning Point Therapeutics Inc.; Kura Oncology Inc.; ArQule Inc.
Get The Full Global Tyrosine Kinase Inhibitors Market Report
Tyrosine Kinase Inhibitors Market Overview
Tyrosine kinase inhibitors (TKI) refer to a class of pharmaceuticals that block several ways protein kinases signal the transduction pathway’s function. It is used in targeted therapy to target and kill cancer cell types while sparing healthy cells.